What is it?
What the human evidence actually shows
7Healthy-adult nootropic benefits remain unproven. A 1996 follow-up involved 14 selected clinical responders using PEA together with selegiline, so it cannot isolate PEA benefits or validate ordinary HCl supplementation. An exercise study measured a urinary metabolite without administering PEA. These observations answer different questions from whether a supplement improves focus or motivation.
How the evidence was assessed
2This profile separates human oral studies from clinical combinations, cell and animal experiments, and regulator guidance. Benefit claims are judged against healthy-adult oral HCl use; product listings supply comparison information rather than efficacy evidence. Sources were checked on 14 October 2026.
Names, aliases and forms
Mechanisms of action
Trace-amine receptor and monoamine context
2Phenylethylamine activates trace amine-associated receptor 1 (TAAR1) in experimental systems and influences monoamine signaling. That explains research interest in the compound, but receptor activity alone does not predict a useful focus, energy or mood effect from an oral product.
What newer cardiovascular research can tell you
13A 2025 study combined human receptor and liver experiments with kinetic modeling to prioritize phenethylamines for safety research. Predicted receptor-active doses are model outputs, not observed human blood-pressure changes, safe limits or nootropic doses. They provide a hazard hypothesis rather than clinical certainty.
Potential effects and evidence map
Grade E for healthy-adult oral nootropic use. Animal and receptor studies support pharmacology, while small human food-exposure and selected clinical combination studies do not validate focus, mood or motivation benefits from PEA HCl supplements.
Receptor and animal findings have not established reliable mental-energy or wakefulness benefits from oral PEA HCl in healthy adults.
A selected clinical series used PEA with selegiline; it cannot isolate PEA effects or establish mood benefits in healthy supplement users.
A focus or attention benefit from oral PEA HCl has not been established in healthy-adult trials.
Rodent reward and movement findings do not establish motivation or productivity benefits in people.
Timing & effect horizon
MAO-B helps metabolize PEA; mouse knockout experiments demonstrate that relationship. Animal clearance figures, internet anecdotes and modeled concentration curves cannot establish a human oral HCl onset, The time for blood levels to fall by half during the final elimination phase.Source or effect duration. No supported timing facts or evidence-based cycling schedule are available for healthy-user nootropic use.
Safety, side effects and risk profile
MAO inhibitors can change PEA metabolism and exposure. Nonselective MAO inhibition and additional stimulants deserve particular caution.
Phenethylamine contracted isolated rat aorta and renal arteries. This supports a cardiovascular hazard concern, especially with existing hypertension or other stimulant exposure.
Experimental psychomotor stimulation supports caution with stimulant combinations; insomnia and anxiety rates in oral HCl users are not established.
Healthy-user efficacy, repeated-use safety and a reliable oral dose-effect relationship remain poorly characterized.
No adequate PEA HCl pregnancy or lactation safety evidence was identified.
Some volunteers reported headache, dizziness or discomfort after 5 mg PEA in apple juice in a small controlled study.
Nausea was among the symptoms summarized in the Dutch assessment of a small oral food-exposure study.
United States (checked 14 October 2026): product listings do not represent FDA premarket safety or effectiveness approval.
In a small controlled study, some volunteers reported headache, dizziness or discomfort after oral PEA in apple juice. This does not establish adverse-event rates for HCl capsules. Cardiovascular experimental findings are discussed separately; severe outcomes reported for stimulant blends or substituted phenethylamines cannot automatically be attributed to plain PEA.
In 2026, phenethylamine directly exposed to isolated rat aorta and renal artery segments caused contraction. This supports a vascular hazard signal, but it does not measure the frequency or severity of cardiovascular events in people taking oral HCl. Existing hypertension or cardiovascular disease is a separate caution context.
Interactions and cautions
PEA is a substrate for MAO-B, so inhibiting that pathway can alter exposure. The small clinical combination report is not a safe-stacking protocol. MAO inhibition varies by drug, dose and selectivity; broad claims that all MAO-B regimens inevitably cause a hypertensive crisis are unsupported. Combining PEA with other stimulants introduces additional pharmacological concern, while interaction magnitudes for individual combinations remain poorly quantified.
Legal and regulatory status
United States, as of 14 October 2026: FDA does not approve dietary supplements for safety or effectiveness before sale. Retail availability is not ingredient-specific approval or a determination that a particular phenylethylamine product is lawful. This statement does not establish EU or other national marketing and import status.
How it compares
Compare phenylethylamine HCl with products that explicitly name the same compound and salt. Palmitoylethanolamide is a different lipid amide; evidence for it does not transfer to phenylethylamine. Substituted phenethylamine stimulants are also different substances, so the class name alone cannot establish equivalent effects or safety.
Practical buying and quality notes
- Compare powder offers per gram of the stated ingredient. For capsules, price per gram = package price / (capsule count × labeled milligrams per capsule / 1,000). For example, 120 capsules labeled 500 mg HCl contain 60 g of labeled HCl in total. Apply the same salt basis before comparing with powder. Shipping, currency, stock and blend ingredients can change the practical comparison; a cheaper row does not establish better evidence or quality.10
- Phenylethylamine free base has molecular weight 121.18; its HCl salt is 157.64. Thus 500 mg of pure HCl contains about 384 mg of phenylethylamine by mass (500 × 121.18 / 157.64). This is a chemical conversion, not a dose recommendation or proof of bioequivalence. Check whether the label states salt mass or an equivalent amount, and look for a batch-matched identity and purity report.10
FAQ
Is a capsule strength a researched dose?
7No. A retailer label describes the amount sold, while an efficacy dose requires a relevant human study. PEA plus selegiline research cannot establish a healthy-user HCl dosing range. Label amounts are for package and price calculations only.
How long does phenylethylamine last?
3A reliable human oral HCl onset and duration have not been established. Rapid metabolism in experimental models does not supply a precise supplement effect window. Claims of a precise short effect, a tolerance-free cycle or a specific redosing interval exceed the available evidence.
References
- PubChem Compound Summary for CID 1001, Phenethylamine.
- Pei Y, Asif-Malik A, Canales JJ. Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications. Front Neurosci. 2016.
- Obata Y, Kubota-Sakashita M, Kasahara T. Phenethylamine is a substrate of monoamine oxidase B in the paraventricular thalamic nucleus. Sci Rep. 2022.
- Ryu IS, Kim OH, Kim JS. Effects of beta-Phenylethylamine on Psychomotor, Rewarding, and Reinforcing Behaviors and Affective State: The Role of Dopamine D1 Receptors. Int J Mol Sci. 2021.
- Szabo A, Billett E, Turner J. Phenylethylamine, a possible link to the antidepressant effects of exercise? Br J Sports Med. 2001.
- U.S. Food and Drug Administration. FDA 101: Dietary Supplements. Accessed 14 October 2026.
- Sabelli H, Fink P, Fawcett J, Tom C. Sustained antidepressant effect of PEA replacement. J Neuropsychiatry Clin Neurosci. 1996;8(2):168-171.
- Luthy J, Schlatter C. Biogenic amines in food: effects of histamine, tyramine and phenylethylamine in the human. Z Lebensm Unters Forsch. 1983;177(6):439-443.
- Netherlands Food and Consumer Product Safety Authority, BuRO. Advice on pharmacologically active substances in food supplements. 9 November 2021.
- PubChem Compound Summary for CID 9075, 2-Phenylethylamine hydrochloride.
- PubChem Compound Summary for CID 4671, Palmitoylethanolamide.
- Pinckaers NET et al. Potential Cardiovascular Risks of Phenethylamine Analogues in Food Supplements: Evidence from Vasocontraction of Rat Artery Segments. Cardiovasc Toxicol. 2026;26:36.
- Pinckaers NET et al. Quantitative in vitro-to-in vivo extrapolation of human adrenergic and trace amine-associated receptor 1 potencies of pre-workout supplement ingredients using physiologically based kinetic modelling-based reverse dosimetry. Arch Toxicol. 2025.
- National Institutes of Health, Office of Dietary Supplements. Dietary Supplements: What You Need to Know. Updated 4 January 2023; accessed 14 October 2026.